TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Five-year data of AGAMREE® (vamorolone) in patients with DMD show improved safety profile with comparable effectiveness to standard of care corticosteroids

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Santhera Pharmaceuticals
Five-year data of AGAMREE® (vamorolone) in patients with DMD show improved safety profile with comparable effectiveness to standard of care corticosteroids

Long-term study of AGAMREE in Duchenne muscular dystrophy patients reveals comparable effectiveness to standard corticosteroids, with significantly lower rates of vertebral fractures and better growth maintenance over five years.

Insights
NVDA   positive

Top holding in both ETFs, indicating strong growth potential and market leadership in technology sector


CPRX   neutral

Mentioned as having out-licensed rights for North America, with no specific performance details